SCF-AMC-DEMO-TOX-OPIOID-CANNABINOID-0001
SCF Advanced Medicine Clinic
Patient-Specific Walkthrough Demonstration
Hydromorphone Hydrochloride + THC-Induced Toxic Encephalopathy
SCF Multi-Omics Neuroimmune Connectomic Reconstruction Platform
Encephalopathy Connectomic Collapse Atlas (ECCA-TOX)
IMPORTANT CLINICAL DISCLAIMER
This demonstration is a hypothetical clinical workflow example for research and systems-design purposes only.
This document is not a treatment recommendation and does not replace emergency evaluation, toxicology consultation, neurology consultation, or standard medical care.
Acute altered mental status, respiratory depression, overdose, or suspected toxic encephalopathy requires immediate medical assessment.
I. PATIENT PRESENTATION
Patient Identifier
AMC-DEMO-001
Age
57 years
Sex
Male
Medical History
- Chronic lumbar radiculopathy
- Osteoarthritis
- Hypertension
- Obstructive sleep apnea
- Mild hepatic steatosis
Medications
Prescribed
Hydromorphone Hydrochloride
8 mg q4h PRN
Self-Administered
High-potency THC concentrate
80–90% THC
Daily
Presentation
Family reports:
- Confusion
- Disorientation
- Excessive somnolence
- Visual hallucinations
- Impaired balance
- Slowed speech
- Reduced responsiveness
Duration:
72 hours
II. SCF TRIAGE MODULE
Immediate Risk Assessment
Airway
Patent
Breathing
Respiratory rate:
10/min
Oxygen saturation:
91%
Circulation
BP:
108/66
HR:
58
Neurologic
GCS:
13
(E3 V4 M6)
Cognitive
MoCA:
14/30
Delirium
CAM-ICU:
Positive
SCF Initial Classification
Primary Diagnosis
Toxic Encephalopathy
Contributing Toxic Drivers
Driver A
μ-Opioid Receptor Hyperactivation
Hydromorphone
Driver B
CB1 Receptor Hyperactivation
THC
Driver C
Respiratory Depression
Driver D
Sleep Fragmentation
OSA
Driver E
Neuroimmune Amplification
Secondary
III. SCF MULTI-OMIC FAULT ARCHITECTURE
Tier 1
Drug-Receptor Overactivation
Hydromorphone
Target:
μ-opioid receptor
Affected Regions:
- PAG
- Nucleus Accumbens
- Brainstem
- Cortex
THC
Target:
CB1 receptor
Affected Regions:
- Hippocampus
- Cerebellum
- Basal ganglia
- Cortex
Tier 2
Neurotransmitter Disruption
Observed
System | Effect |
Glutamate | Suppressed |
Acetylcholine | Reduced |
Dopamine | Dysregulated |
GABA | Increased |
Orexin | Reduced |
Tier 3
Connectomic Collapse
Affected Networks
- Default Mode Network
- Salience Network
- Executive Network
- Ascending Reticular Activating System
Tier 4
Autonomic Dysfunction
Manifestations
- Bradycardia
- Hypoventilation
- HRV suppression
IV. SCF ADVANCED MEDICINE CLINIC WORKUP
Laboratory Panel
Toxicology
Marker | Result |
Hydromorphone | Elevated |
THC Metabolites | Elevated |
Alcohol | Negative |
Benzodiazepines | Negative |
Metabolic
Marker | Result |
Glucose | Normal |
Sodium | Normal |
Ammonia | Normal |
Lactate | Mildly Elevated |
Neuroinjury
Marker | Result |
GFAP | 240 pg/mL |
NfL | 18 pg/mL |
S100B | 0.18 ng/mL |
Interpretation:
Mild acute neuroglial stress
V. SCF CONNECTOMIC ASSESSMENT
qEEG
Findings
- Increased theta
- Increased delta
- Reduced alpha coherence
HRV
SDNN
42 ms
Interpretation:
Autonomic suppression
Cognitive Profile
Domain | Status |
Attention | Impaired |
Working Memory | Impaired |
Executive Function | Impaired |
Orientation | Impaired |
VI. SCF BIOMARKER RESPONSE DASHBOARD
Hyperacute Monitoring
Every 6 Hours
Marker | Threshold |
Respiratory Rate | >12/min |
O₂ Saturation | >94% |
GCS | Stable or improving |
CAM-ICU | Improving |
HRV | Improving |
Daily Biomarkers
Biomarker | Target |
GFAP | ↓ 10–20% |
S100B | ↓ |
IL-6 | ↓ |
Lactate | Normalization |
VII. SCF PRECISION ACUPUNCTURE DEMONSTRATION
Clinical Status
Patient stabilized
No respiratory compromise
No active overdose
Medical clearance obtained
Cohort A
Session 1
Points
- GV20
- PC6
- ST36
- HT7
- Yintang
Duration
15 minutes
Goal
Autonomic stabilization
Monitoring
Pre/Post Session
Endpoint | Baseline | Post |
HR | 58 | 64 |
SDNN | 42 | 49 |
CAM-ICU | Positive | Improved |
Alertness | Reduced | Improved |
Week 2 Progression
Additional Points
- LI4
- LI11
- GV24
- SP6
Objective
Neuroimmune stabilization
Executive network recovery
VIII. SCF REAL-TIME ESCALATION MODEL
Escalation allowed if:
Cognitive
MoCA improvement
≥2 points
Neuroglial
GFAP reduction
≥15%
Autonomics
SDNN increase
≥10%
Connectomics
qEEG coherence increase
≥10%
IX. DE-ESCALATION MODEL
Immediate review if:
Neurologic
GCS decrease
≥2 points
Biomarker
GFAP increase
≥25%
OR
NfL increase
≥25%
Clinical
New hallucinations
Worsening confusion
Respiratory suppression
X. SCF PREDICTIVE FORECAST
Recovery Probability
Favorable Indicators
- Normal ammonia
- Mild NfL elevation
- Mild GFAP elevation
- Preserved MRI
- Reversible toxic exposure
Predicted Outcome:
High likelihood of cognitive recovery after toxic exposure resolution.
High-Risk Indicators
If present:
- Persistent hypoxia
- Escalating NfL
- Progressive qEEG slowing
- Structural MRI abnormalities
Predicted Outcome:
Persistent toxic-connectomic dysfunction
XI. SCF AMC FINAL CASE CLASSIFICATION
SCF Diagnosis
Opioid-Cannabinoid Toxic Encephalopathy
Subtype:
Hydromorphone + High-Potency THC Connectomic Suppression Syndrome
Dominant SCF Faults
- μ-Opioid Receptor Overactivation
- CB1 Hyperactivation
- Ascending Reticular Activating System Suppression
- Executive Network Dysfunction
- Autonomic Suppression
- Neuroglial Stress Response
SCF Connectomic Severity Score
42/100
Classification:
Moderate Toxic Connectomic Collapse
Clinical Priority Targets
- Respiratory stabilization
- Cognitive recovery
- Autonomic normalization
- Neuroimmune stabilization
- Connectomic restoration
- Relapse prevention
MASTER REGISTRY INDEX
- SCF-AMC-DEMO-TOX-OPIOID-CANNABINOID-0001 — Hydromorphone + THC Toxic Encephalopathy Walkthrough
- SCF-ECCA-TOX-0001 — Toxic Encephalopathy Module
- SCF-ECCA-TOX-BIO-0011 — Toxic Encephalopathy Biomarker Panel
- SCF-ECCA-TOX-ACU-0011 — Toxic Encephalopathy Acupoint Neuro-Circuit Atlas
- SCF-CLINDEV-0001 — SCF Clinical Development Framework
- SCF-BIOMARKER-ENDPOINTS-0001 — SCF Biomarker Endpoint Validation Framework
- SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema